Navigating the Latest Options for the Treatment of CKD in T2D

Download All
In this series of microlearning modules, expert faculty provide insight on new evidence and treatment for chronic kidney disease in type 2 diabetes to improve kidney and cardiovascular outcomes.
Jennifer B. Green, MD

SGLT2 Inhibitors in T2D with CKD

In this microlearning module, an expert faculty provides an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes.

Jennifer B. Green, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: July 12, 2022 Expired: No longer available for credit

A leading expert provides an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes.

Jennifer B. Green, MD Released: July 12, 2022

Dr Jennifer B. Green summarizes key findings that underpin use of SGLT2 inhibitors in patients with diabetic kidney disease.

Jennifer B. Green, MD Released: July 21, 2022
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
Bayer HealthCare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings